| GBT Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the GBT shares outstanding history going back to 8/12/2015:
Also see: GBT Market Cap History GBT YTD Return |
GBT Shares Outstanding History — Global Blood Therapeutics Share Count Over Time
As of 8/4/2022 Global Blood Therapeutics has 67.46 million GBT shares outstanding. Investors often track the GBT shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows GBT share count trends over time, with 31 historical shares outstanding datapoints presented, dating back to 8/12/2015.
| GBT Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GBT Historical Shares Outstanding: +13.53% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| GBT Stock Price Chart |
| About Global Blood Therapeutics Inc |
| Global Blood Therapeutics is a biopharmaceutical company that engaged in the discovery, development and delivery of treatments to underserved patient communities. The U.S. Food and Drug Administration has granted approval for Co.'s Oxbryta® (voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children 12 years of age and older. Oxbryta, an oral therapy taken once daily, is the treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD. Co. is developing treatments for SCD, including inclacumab, a P-selectin inhibitor used to reduce the incidence of vaso-occlusive crises and hemoglobin polymerization inhibitor, GBT021601, or GBT601. We show 31 historical shares outstanding datapoints in our coverage of GBT's shares outstanding history. Understanding the changing numbers of GBT shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like GBT versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching GBT by allowing them to research GBT shares outstanding history as well as any other stock in our coverage universe. |
| GBT Current Stock Quote |
Quotes delayed 20 minutes  Free GBT Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| GBT Share Performance |
| Shares Outstanding Peers |
| Global Blood Therapeutics (GBT) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
GCTK Shares Outstanding History GEHC Shares Outstanding History GEMP Shares Outstanding History GENE Shares Outstanding History GERN Shares Outstanding History GFOR Shares Outstanding History GH Shares Outstanding History GHDX Shares Outstanding History GILD Shares Outstanding History GKOS Shares Outstanding History More Healthcare companies » |
GBT Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
